Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dalitong Granules (达立通颗粒) is an approved Traditional Chinese Medicine (TCM) oral granule formulation developed and manufactured by Nanchang Hongyi Pharmaceutical. It is specifically indicated for the treatment of motility disorder-type functional dyspepsia and gastroparesis, particularly in patients presenting with liver-stomach stagnant heat syndrome. The formulation is composed of several herbal ingredients, including Bupleurum (柴胡), Fructus Aurantii Immaturus (枳实), Aucklandia (木香), Citrus Reticulata Peel (陈皮), Pinellia (清半夏), Taraxacum (蒲公英), and Hawthorn (山楂). These components work synergistically to alleviate symptoms such as epigastric fullness, belching, poor appetite, gastric burning, and acid reflux. The product is registered in China under the approval number 国药准字Z20050001.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dalitong Granules.